Last $52.04 USD
Change Today +0.08 / 0.15%
Volume 139.7K
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals (LGND) Snapshot

Open
$51.96
Previous Close
$51.96
Day High
$52.17
Day Low
$51.28
52 Week High
02/14/14 - $80.42
52 Week Low
09/26/13 - $39.75
Market Cap
1.1B
Average Volume 10 Days
381.5K
EPS TTM
$0.37
Shares Outstanding
20.8M
EX-Date
04/3/07
P/E TM
140.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGAND PHARMACEUTICALS (LGND)

ligand pharmaceuticals (LGND) Related Businessweek News

View More BusinessWeek News

ligand pharmaceuticals (LGND) Details

Ligand Pharmaceuticals Incorporated, a biotechnology company, acquires and develops royalty revenue generating assets in the United States. Its late-stage development programs include Promacta, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Captisol-enabled Melphalan IV for the multiple myeloma transplant setting; Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis; and Nexterone, an injectable formulation. The company’s late-stage development programs that are in Phase III clinical trials comprise Captisol-enabled Noxafil-IV; MK-8931 Beta-Secretase Inhibitor program for the treatment of Alzheimer’s disease; Captisol-enabled Carbamazepine-IV for the management of acute seizure disorder for hospital or emergency settings; and Captisol-enabled Delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections. It also offers Sparsentan that is in Phase II clinical trials for kidney diseases; Lasofoxifene, an estrogen partial agonist for osteoporosis treatment and other diseases; and Captisol-enabled Topiramate Injection, which is in Phase I clinical trials for the treatment of partial onset or primary generalized tonic-clonic seizures. In addition, the company’s preclinical stage products include HepDirect for liver diseases; Oral Human Granulocyte Colony Stimulating Factor for the treatment of Neutropenia; and IRAK4 Inhibitor for inflammation. Further, it provides Glucagon Receptor Antagonist that is in Phase I clinical trials for diabetes; Selective Androgen Receptor Modulator, which is in Phase II clinical trials for the therapeutic benefits; and Captisol-Enabled Clopidogrel that is in Phase III clinical trials for anti-coagulants. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.

ligand pharmaceuticals (LGND) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $500.3K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $294.6K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $368.1K
Vice President, General Counsel and Secretary
Total Annual Compensation: $283.4K
Compensation as of Fiscal Year 2013.

ligand pharmaceuticals (LGND) Key Developments

Ligand Pharmaceuticals Incorporated Signs Commercial License Agreement with Avion Pharmaceuticals, LLC

Ligand Pharmaceuticals Incorporated announced the signing of a commercial license agreement with Avion Pharmaceuticals, LLC for the development and commercialization of four Captisol-enabled programs. Under the terms of the agreement, Ligand is entitled to receive an up-front payment, and is eligible to receive revenue from Captisol material sales, potential milestone payments, and royalties on future net sales of the products containing Captisol.

Ligand Pharmaceuticals Mulls Acquisitions

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) is looking for acquisitions. Ligand Pharmaceuticals Incorporated has announced a proposed offering of $225 Million of convertible senior notes and may use a portion of the net proceeds to acquire new businesses through one or more strategic transactions.

Ligand Pharmaceuticals Incorporated Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter of 2014; Revised Earnings Guidance for the Full Year of 2014

Ligand Pharmaceuticals Incorporated announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $10,608,000 compared with $9,580,000 for the same period a year ago. Gain from operations was $1,358,000 compared with $1,514,000 for the same period a year ago. Income from continuing operations was $1,288,000 or $0.07 per diluted share compared with $3,694,000 or $0.18 per diluted share for the same period a year ago. Net income attributable to Ligand common shareholders was $1,592,000 or $0.07 per diluted share compared with $6,091,000 or $0.30 per diluted share for the same period a year ago. Non-GAAP net income from continuing operations attributable to common shareholders was $5,168,000 or $0.24 per diluted share compared with $2,479,000 or $0.12 per diluted share for the same period a year ago. Royalty revenues increased 7% to $5.2 million from $4.9 million for the same period in 2013 primarily due to higher royalties from Promacta(TM) and Kyprolis(R). Material sales were $3.5 million as compared to $4.0 million for the same period in 2013 due to timing of customer purchases of Captisol for both clinical and commercial uses. Collaborative research and development and other revenues increased to $1.9 million from $0.7 million for the same period in 2013 due primarily to an upfront license fee earned from TG Therapeutics for the licensing of IRAK-4 in the second quarter of 2014. For the six months, the company reported total revenues of $26,566,000 compared with $21,231,000 for the same period a year ago. Gain from operations was $6,458,000 compared with $5,447,000 for the same period a year ago. Income from continuing operations was $3,384,000 or $0.17 per diluted share compared with $4,998,000 or $0.24 per diluted share for the same period a year ago. Net income attributable to Ligand common shareholders was $3,688,000 or $0.17 per diluted share compared with $7,586,000 or $0.37 per diluted share for the same period a year ago. Non-GAAP net income from continuing operations attributable to common shareholders was $12,511,000 or $0.57 per diluted share compared with $6,923,000 or $0.34 per diluted share for the same period a year ago. Royalty revenues increased 22% to $13.1 million from $10.7 million for the same period in 2013 primarily due to higher royalties from Promacta and Kyprolis. Material sales increased to $9.2 million from $5.5 million for the same period of 2013 due to timing of customer purchases of Captisol as well as an increase in purchases for use in clinical trials. Collaborative research and development and other revenues declined to $4.3 million from $5.0 million for the same period in 2013 primarily due to timing of upfront fees and milestones earned. The company provided earnings guidance for the third quarter of 2014. For the third quarter of 2014, the company expects total revenues to be between $13 million and $14 million, and non-GAAP earnings per diluted share to be between $0.26 and $0.29. The non-GAAP earnings per diluted share guidance does not include changes in contingent liabilities, mark-to-market adjustment for amounts owed to licensors and non-cash stock-based compensation expense. The company revised earnings guidance for the full year of 2014. For the full year of 2014, the company now expects total revenues to be between $64 million and $66 million, and non-GAAP earnings per diluted share to be between $1.50 and $1.55. This is higher than previous guidance, which called for total revenues to be between $62 million and $64 million, and non-GAAP earnings per diluted share to be between $1.40 and $1.45. Effective tax rate to be less than 5% for the next several years.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGND:US $52.04 USD +0.08

LGND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LGND.
View Industry Companies
 

Industry Analysis

LGND

Industry Average

Valuation LGND Industry Range
No financial data is available for LGND.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS, please visit www.ligand.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.